Dr-COVID: Graph Neural Networks for SARS-CoV-2 Drug Repurposing

The 2019 novel coronavirus (SARS-CoV-2) pandemic has resulted in more than a million deaths, high morbidities, and economic distress worldwide. There is an urgent need to identify medications that would treat and prevent novel diseases like the 2019 coronavirus disease (COVID-19). Drug repurposing is a promising strategy to discover new medical indications of the existing approved drugs due to several advantages in terms of the costs, safety factors, and quick results compared to new drug design and discovery. In this work, we explore computational data-driven methods for drug repurposing and propose a dedicated graph neural network (GNN) based drug repurposing model, called Dr-COVID. Although we analyze the predicted drugs in detail for COVID-19, the model is generic and can be used for any novel diseases. We construct a four-layered heterogeneous graph to model the complex interactions between drugs, diseases, genes, and anatomies. We pose drug repurposing as a link prediction problem. Specifically, we design an encoder based on the scalable inceptive graph neural network (SIGN) to generate embeddings for all the nodes in the four-layered graph and propose a quadratic norm scorer as a decoder to predict treatment for a disease. We provide a detailed analysis of the 150 potential drugs (such as Dexamethasone, Ivermectin) predicted by Dr-COVID for COVID-19 from different pharmacological classes (e.g., corticosteroids, antivirals, antiparasitic). Out of these 150 drugs, 46 drugs are currently in clinical trials. Dr-COVID is evaluated in terms of its prediction performance and its ability to rank the known treatment drugs for diseases as high as possible. For a majority of the diseases, Dr-COVID ranks the actual treatment drug in the top 15.

[1]  D. Jans,et al.  The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro , 2020, Antiviral Research.

[2]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[3]  Max Welling,et al.  Semi-Supervised Classification with Graph Convolutional Networks , 2016, ICLR.

[4]  Bo Wang,et al.  Machine Learning for Integrating Data in Biology and Medicine: Principles, Practice, and Opportunities , 2018, Inf. Fusion.

[5]  Catharine I Paules,et al.  Coronavirus Infections-More Than Just the Common Cold. , 2020, JAMA.

[6]  J. Weng.  Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives , 2020, Molecular Plant.

[7]  F. Cheng,et al.  Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 , 2020, Cell Discovery.

[8]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[9]  D. Rader,et al.  Teaching Old Drugs New Tricks: Statins for COVID-19? , 2020, Cell Metabolism.

[10]  Davide Eynard,et al.  SIGN: Scalable Inception Graph Neural Networks , 2020, ArXiv.

[11]  Xin Chen,et al.  Thiopurine Analogue Inhibitors of Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease, a Deubiquitinating and deISGylating Enzyme , 2009, Antiviral chemistry & chemotherapy.

[12]  Qingbo Xu,et al.  In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19 , 2020, Cell Metabolism.

[13]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[14]  Tiziana di Matteo,et al.  Graph Theory Enables Drug Repurposing – How a Mathematical Model Can Drive the Discovery of Hidden Mechanisms of Action , 2013, PloS one.

[15]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[16]  F. Swirski,et al.  Cytokine storm and sepsis disease pathogenesis , 2017, Seminars in Immunopathology.

[17]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[18]  R. Bowen,et al.  Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light , 2020, bioRxiv.

[19]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target , 2020, Intensive Care Medicine.

[20]  Jure Leskovec,et al.  Modeling polypharmacy side effects with graph convolutional networks , 2018, bioRxiv.

[21]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[22]  Alimuddin Zumla,et al.  Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.

[23]  Eun-Hee Kim,et al.  The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts , 2017, Heart and Vessels.

[24]  Alex H. Wagner,et al.  DGIdb 3.0: a redesign and expansion of the drug–gene interaction database , 2017, bioRxiv.

[25]  Jure Leskovec,et al.  Inductive Representation Learning on Large Graphs , 2017, NIPS.

[26]  Russ B. Altman,et al.  A global network of biomedical relationships derived from text , 2018, Bioinform..

[27]  George Karypis,et al.  Few-shot link prediction via graph neural networks for Covid-19 drug-repurposing , 2020, ArXiv.

[28]  Albert-László Barabási,et al.  Network-based approach to prediction and population-based validation of in silico drug repurposing , 2018, Nature Communications.

[29]  Shasha Li,et al.  Drug-Drug Interaction Extraction via Recurrent Neural Network with Multiple Attention Layers , 2017, ADMA.

[30]  Marinka Zitnik,et al.  Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19 , 2020, ArXiv.

[31]  Zhongming Zhao,et al.  Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. , 2014, Journal of the American Medical Informatics Association : JAMIA.

[32]  Yan Zhao,et al.  The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China , 2020, Clinical Immunology.

[33]  M. Vidal,et al.  A genome-wide positioning systems network algorithm for in silico drug repurposing , 2019, Nature Communications.

[34]  Pietro Liò,et al.  Graph Attention Networks , 2017, ICLR.

[35]  A. Barabasi,et al.  Network-based in silico drug efficacy screening , 2016, Nature Communications.

[36]  Michael L. Mussa.  Global Economic Prospects , 2002 .

[37]  S. Jockusch,et al.  A Library of Nucleotide Analogues Terminate RNA Synthesis Catalyzed by Polymerases of Coronaviruses Causing SARS and COVID-19 , 2020, bioRxiv.

[38]  Wen Zhang,et al.  A multimodal deep learning framework for predicting drug-drug interaction events , 2020, Bioinform..

[39]  R. Agha,et al.  World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19) , 2020, International Journal of Surgery.

[40]  Rafael C. Jimenez,et al.  The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases , 2013, Nucleic Acids Res..

[41]  Hongzhou Lu,et al.  Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle , 2020, Journal of medical virology.

[42]  Dexter Hadley,et al.  Systematic integration of biomedical knowledge prioritizes drugs for repurposing , 2017, bioRxiv.

[43]  Pierre Vandergheynst,et al.  Geometric Deep Learning: Going beyond Euclidean data , 2016, IEEE Signal Process. Mag..